Fifth Milestone Achieved by HemoShear with Novel Compounds for Second Target

CHARLOTTESVILLE, Va., Sept. 21, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc ( Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive drug discovery agreement established in January 2019.

Doubling the University of Maryland BioPark's lab space, the two-phase 4MLK development project will represent more than $320 million in total capital investment

BALTIMORE, Sept. 22, 2022 /PRNewswire/ -- University of Maryland, Baltimore (UMB) and Wexford Science & Technology, LLC, announced today that 4MLK, the newest development project in the University of Maryland BioPark, is slated to move forward, with groundbreaking this fall (2022) and delivering in summer 2024. The 8-story, 250,000-square-foot building, Phase I of a two-phase project representing a $320 million total capital investment, will provide critical wet laboratory space in downtown Baltimore for researchers and companies, flexible lab and office/support space for start-ups, and Class A office space, along with areas for convening and a conference center.

ROCKVILLE, Md., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor. The Company’s new 67,000 square-foot facility significantly increases its in-house manufacturing capacity, as well as research and process development lab space. This investment represents a major milestone in MaxCyte’s growth and its ability to support customers and partners in their journey through therapeutic development to commercialization.

The U.S. bioeconomy is booming. Valued at nearly one trillion dollars and predicted to grow globally to over $30 trillion over the next two decades, bioproducts now include everything from the food that we eat to the vaccines we put in our arms. Plant-based burgers, recyclable bioplastics, concrete, clothing, and microbes for mining minerals are just a few of the latest bio-based products coming to market.

Image: White House Inks Strategy to Grow Trillion Dollar[+] DALL-E X JOHN CUMBERS

OAKLAND, Calif. - President Biden revived his call for a nationwide cancer moonshot effort on Monday, as he marked the 60th anniversary of President Kennedy's famous pledge to get a man on the moon.

"The goal is to cut cancer death rates by at least 50%, at least 50% in the next 25 years," said President Biden, "To turn more cancers from death sentences into chronic diseases people can live with."

Image: https://www.ktvu.com

Startup companies have traditionally looked for the most experienced venture capitalists they could find to get their businesses off the ground and support their growth. That’s not always the case anymore, according to a study by University of Maryland Robert H. Smith School Associate Professor Rich Mathews and his co-author Naveen Khanna of Michigan State University. They argue that startups straight out of the gate are often deciding to work with new venture capitalists rather than established ones.

One of Maryland’s premiere medical networks just announced an eight-figure investment into the economic development of local and marginalized communities by way of notable funding entities.

The University of Maryland Medical System (UMMS) said in a Thursday statement that it will commit  $14 million to  11 community development financial institutions and privity equity firms throughout the state. The investment is intended to address racial, economic and environmental disparities in the communities the system serves.

Image: The University of Maryland Medical Center in Baltimore. (Photo by Flickr user Baltimore Heritage, used via a Creative Commons license)

CHARLOTTESVILLE, Va., Sept. 15, 2022 /PRNewswire/ -- AMPEL BioSolutions today announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case. The company's new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time and potentially stem the serious illness caused by SARS-CoV-2 infection that can lead to lung damage or death.

AMPEL's new genomic test, known as CovGENE®, has been validated by a longitudinal study in partnership with physicians in the Division of Pulmonary and Critical Care Medicine of the University of Virginia Medical Center. With careful analysis of patients admitted to the UVA Intensive Care Unit, CovGENE® demonstrated remarkable precision with a greater than 90-percent rate of accuracy. CovGENE®, can be administered by drawing a patient's blood to quickly ascertain whether a Covid-19 patient will have a mild, moderate, or severe outcome. The findings are detailed in a paper published today by Frontiers in Immunology.

Waltham, Mass. and Dublin – August 15, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.

ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. Q32 has recently completed a biomarker-enabled Phase 1 study characterizing pharmacokinetics, pharmacodynamics and safety of ADX-914 that demonstrated pharmacological effect on T cells in healthy volunteers. Q32 expects to initiate a Phase 2 trial in atopic dermatitis later this year and is planning to initiate a Phase 2 trial in a second autoimmune disease next year.

La Vista, Nebraska — September 14, 2022 – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres' Nanotrap® technology platform.

"Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers," said Ceres CEO Ross Dunlap. "We are thrilled to have Streck's support and guidance in this next, exciting phase of our growth."

Swimming with Sharks pairs aspiring healthcare entrepreneurs with successful innovators and investors. The startups selected will pitch at the American Society of Anesthesiologists (ASA) Annual Meeting, ANESTHESIOLOGY®, in October 2022.

There will be two Swimming with Sharks sessions at the event: one for very early-stage startups (back of the napkin ideas/conceptual/pre-seed stage) and one for startups that are seed stage and beyond (ie series A).

September 13, 2022—The Maryland Stem Cell Research Commission announced it will grant $4,165,325 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland. Awardees submitted proposals to the Commission in response to its Request for Applications (RFAs) for its first round of funding cycle in fiscal year 2023.

Recipients include 12 scientists accelerating research at Johns Hopkins University, University of Maryland, Baltimore County, University of Maryland, College Park, and the University of Maryland, Baltimore. Their research addresses an array of medical conditions, such as cancer, eye, heart, bone, blood, digestive, and immune system diseases.

- The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations –

DUBLIN--(BUSINESS WIRE)--Sep. 12, 2022-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity as defined by the European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score of ≥ 5. At Week 24, patients treated with dazodalibep achieved a 6.3-point reduction in their ESSDAI score and patients treated with placebo achieved a 4.1-point reduction, resulting in a statistically significant least squares mean difference of 2.2 points (p=0.017).

The Biden administration announced the launch of a new national program dedicated to fortifying America’s biotechnology manufacturing industry in the latest executive effort to keep U.S. supply chains competitive.

Introduced Sunday via executive order, the Biotechnology and Biomanufacturing Initiative focuses on a specific biomanufacturing process that uses microorganisms to create chemicals and compounds that contribute to make medicines, fuels and other input materials.

As the number of monkeypox cases around the world has ballooned since early May, so too has the list of diagnostic developers rapidly churning out tests for the virus.

Latest to join the likes of Labcorp, Roche, BD, Cepheid and others in that mission is Qiagen, which announced this week the launch of a monkeypox assay of its own. The test is designed to be analyzed by the company’s QIAstat-Dx PCR testing system.

Image: The QIAstat-Dx Viral Vesicular Panel is indicated for research use only, making Qiagen’s test available to the approximately 3,000 laboratories around the world that already have QIAstat-Dx PCR analyzers installed. (Qiagen)

NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. ( NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations, is proud to recognize and celebrate multiple significant milestones from its position of leadership in New York City's commercial life science cluster. These milestones include (1) 20 years since Alexandria Venture Investments made its first NYC venture investment in Intra-Cellular Therapies' Series A financing in 2002; (2) 17 years since Alexandria was awarded the New York City Economic Development Corporation's (NYCEDC) request for proposal (RFP) in 2005 to develop and operate what the company has transformed into the Alexandria Center® for Life Science – New York City, the city's first and only commercial life science campus; (3) 12 years since the Alexandria Center officially opened to welcome its first tenants in 2010; and (4) five years since it unveiled the inaugural site of Alexandria LaunchLabs®, the company's world-class life science startup platform, at the Alexandria Center in 2017, which was followed by Columbia University's election in 2019 to establish a second NYC-based Alexandria LaunchLabs site on the university's medical school campus.

– Winner to be announced as part 2022 BioHealth Capital Region Forum –

ROCKVILLE, MARYLAND, September 12, 2022 – A panel of investor judges and anROCKVILLE, MARYLAND, September 12, 2022 – A panel of investor judges and anaudience of industry leaders will gather for the presentations of five early-stage companiesat the 7th Annual BioHealth Capital Region Crab Trap Competition at US Pharmacopeia onSeptember 21st in Rockville, Maryland. Created in 2016, the competition highlights thecommercialization potential of biohealth technologies throughout the region and beyond.

Click here to download the PDF

New York, NY, September 6, 2022 | Gradian Health Systems (Gradian) is proud to announce a strategic relationship with Canon Virginia Inc. (CVI). This announcement marks the collaboration of two mission driven organizations, with a common goal of addressing disparities within healthcare globally.

This collaboration builds on Gradian’s decade plus work developing and supporting medical technology in resource-limited settings and CVI’s 37 years of established manufacturing excellence and medical device expertise. CVI will assume manufacturing operations for Gradian’s flagship product, the UAM, an anesthesia machine designed to work in the absence of electricity and medical oxygen, and establish manufacturing operations for Gradian’s newest product – the K-O2. CVI plans to be in full scale production of both products by the end of 2022. The UAM and K-O2 are specifically designed to better enable access to anesthesia and oxygen therapy, respectively, by addressing resource constraints that often prevent medical providers from being able to deliver continuous care for patients.

President Joe Biden plans to appoint longtime biologist and former government scientist Renee Wegrzyn as the first director of the nascent Advanced Research Projects Agency for Health.

Biden’s announcement comes as ARPA-H advocates debate where the multibillion-dollar agency should be headquartered and which elusive disease areas should be prioritized. The president officially launched the agency in March with $1 billion in initial funding allotted by Congress, but the search for its inaugural director has taken months.

Image: Renee Wegrzyn will serve as the first director of the Advanced Research Projects Agency for Health. WHITE HOUSE PHOTO

GERMANTOWN, Md., Sept. 8, 2022 /PRNewswire/ -- Deka Biosciences ("Deka"), a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases, announced today the appointment of Charlotte Moser, MD, PhD, MSc, MBA as Chief Medical Officer (CMO) and Deb Kientop, MBA as Vice President, Clinical Operations.

Charlotte Moser, MD, PhD, MSc, MBA, Chief Medical Officer (CMO), Deb Kientop as Vice President, Clinical Operations at Deka Biosciences "We are proud to have both Charlotte and Deb joining Deka during this exciting time," said John Mumm, Chief Executive Officer, Deka. "Both come to Deka with strong experience, knowledge and expertise, which will help to deliver life-saving therapies to patients, and drive expansion of our platform, and overall growth of Deka."

Image: Charlotte Moser, MD, PhD, MSc, MBA, Chief Medical Officer (CMO), Deb Kientop as Vice President, Clinical Operations at Deka Biosciences

A subsidiary of United Therapeutics ($UTHR) has placed an order for up to 1,000 unmanned aerial vehicles (UAVs) from Chinese manufacturer EHang. The plan is to use the UAVs, flying vehicles more commonly known as drones, to ship manufactured lungs and other organs from production facilities to hospitals for transplantation.

The National Institutes of Health has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 tests, with a major focus on accessibility. The funding opportunities are part of the Rapid Acceleration of Diagnostics (RADx) Tech program, managed by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The new programs may award up to $300 million in funds from the American Rescue Plan Act of 2021 to support the accelerated development of tests and provide regulatory guidance during the COVID-19 pandemic and beyond.

September 07, 2022 08:00 AM Eastern Daylight Time

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company controlling the world’s largest therapeutic phage library initiative and dedicated to providing therapies to treat infectious diseases, today announced “The AMR RAPID™ Challenge” at the World AMR Congress. RAPID is APT’s acronym for Rapidly Adaptive Phage for Infectious Disease.

Through this challenge, APT will pay $1,000 to any individual or institution in the clinical research community that identifies a strain of bacteria (within the CDC's most serious and urgent biological threat categories -- i.e., the "ESKAPE" pathogens*) for which APT cannot demonstrate sensitivity to with its phage bank. Applicants to the AMR RAPID™ Challenge should contact This email address is being protected from spambots. You need JavaScript enabled to view it. for further information, rules, and conditions or visit phagebank.com.

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients

September 08, 2022 07:00 AM Eastern Daylight Time

GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis’ SUREtechnology Platform™, a suite of cell line development technologies that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines.

I'm pleased to share with you JHTV's annual report for Fiscal Year 2022. As we returned to the office last year and The Johns Hopkins University came back to life, we wanted to celebrate the vibrancy of the innovation environment on our campuses and our connection to the broader Baltimore startup ecosystem. As we see new technologies, new companies and new alumni launch from our Homewood and East Baltimore campuses, so, too, do we see the city continue to become a growing hub for innovation.

LEIDEN, September 8, 2022 - MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel as Chair of its Board of Directors.

Dhaval Patel is Executive Vice President and Chief Scientific Officer at UCB, Belgium, clinical professor at the University of North Carolina Chapel Hill, and former Head of Research for the Novartis Institutes for BioMedical Research Europe.

Just Funded selected the organizations listed in this article based on:

• Track record
• Executive leadership
• Market share
• Innovation
• ESG rating

Shannon Wolfson from BlueCloudTV Interviews Dr. Harsha Rajasimha, Founder and CEO of Jeeva eClinical Cloud. The story behind the company and the vision to increase diversity in clinical trials.

On its first day as a publicly traded company Wednesday, Rockville-based Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) saw its shares climb a staggering 373% to close at $38.48. At one point late Wednesday, its shares were trading at above $65 — up more than 700% from their opening price.

In after-hours trading Wednesday, the stock was down about 17% from its close and trading around $32 a share.

The eye-popping gains came on a day when all the major U.S. stock indexes fell.

Brett Shealy, Executive Director of the Life Sciences Banking Team with J.P.Morgan, joins Rich Bendis on BioTalk to discuss his Career, BioHealth Investment, and the upcoming 2022 BioHealth Capital Region Forum/Investment Conference/Crab Trap.

Listen now via Apple https://apple.co/3cK8ScJ, Google https://bit.ly/3etce4h, Spotify https://spoti.fi/3cNdIpo, Amazon Podcasts https://amzn.to/3eucMXi, or TuneIn https://bit.ly/3Rj8wIJ

The first time Kurt Newman walked into the Children’s National Hospital atrium as a thirtysomething surgical fellow in 1984, he felt like he was home. He didn’t want to leave.

Nearly four decades later, Newman is announcing his retirement as the D.C. pediatric hospital’s president and CEO.

Image: Dr. Kurt Newman, president and CEO of Children's National Hospital, has spent 11 years in the role. EMAN MOHAMMED

Thank you for your interest in joining the Entrepreneurship Lab Equity Incubator at the Universities at Shady Grove! We will be accepting teams and individuals. You may apply individually, although we recommend having at least one other team member.

For this program, we are inviting individuals who identify with a gender, racial/ethnic, or other identity which, historically has not been dominant in receiving entrepreneurship support. We do this because we aim to create a collaborative, diverse cohort of entrepreneurs that can contribute unique perspectives in a supportive environment as we foster new venture formation and growth.

Download the PDF

Click here to learn more.

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection. Emergent and CEPI (the Coalition for Epidemic Preparedness Innovations) are co-funding this program.

“Over the last 24 years, Emergent’s mission to protect and enhance life and commitment to help mitigate public health threats have remained unchanged,” said Kelly Warfield, Ph.D., SVP for research and development at Emergent BioSolutions. “We are proud to deploy our product development and partnering capabilities to address emerging infectious diseases like Lassa fever, for which there is currently no approved vaccine or therapeutic, and to advance our pipeline for patients.”

• The competition nurtures young scientists around the globe
• QIAGEN-Verogen generously donated a combined instrument and reagents prize package worth up to $ 60,000
• Three young forensic scientists have been recognized for work in human identification (HID) and forensics

Germantown, Maryland, and Hilden, Germany, September 5, 2022 -- QIAGEN today announced the winners of its second Young Investigator Awards (YIA). The winner and two runners-up were recognized for their outstanding scientific work using next-generation sequencing (NGS) in human identification (HID). The competition encourages and supports new generations of forensic scientists who show potential to make a lasting impact on human identity and forensics. The three finalists were honored during the International Society for Forensic Genetics (ISFG) Congress in Washington D.C.

The 2022 Young Investigator Award went to Maria Martin Agudo, a PhD candidate at the Department of Forensic Sciences (Forensic Genetics Research Group), Oslo University Hospital in Norway. Haley Omeasoo from The University of Montana, USA and Chiara Fantinato from the Department of Forensic Sciences, Oslo University Hospital, Norway, were the two runners-up. All three finalists received all-inclusive invitations to the International Society for Forensic Genetics (ISFG) Congress.

GENOME WEB, CHICAGO, IL, September 1, 2022 - - After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.

This summer, the firm had an early-access release of a series of gene expression tests coupled with analysis and clinical decision support, starting with LuGene®, a blood test for systemic lupus erythematosus, and DermaGene®, a skin biopsy test to differentiate between several dermatological conditions including psoriasis, scleroderma, and atopic dermatitis.

The Richmond region has won a $52.9 million federal grant to create a hub for research and advanced manufacturing of essential medicines and pharmaceutical ingredients.

The White House announced the grant to the Virginia Biotechnology Research Partnership Authority on Friday. It is among 21 projects that will receive grants from the Build Back Better Regional Challenge, using a $1 billion fund created under the American Rescue Plan Act to generate economic opportunities in disadvantaged communities that need them.

The grant will support six projects in the proposed Advanced Manufacturing Pharmaceutical Cluster, an initiative aimed at bringing new manufacturing opportunities to Petersburg, supporting research at the Virginia Bio + Tech Park in Richmond and boosting work by the Medicines for All Institute at Virginia Commonwealth University to build a national supply of essential medicines.

Click here to read more via Richmond.com